CincyTech-backed Eikonoklastes Therapeutics receives FDA approval for first-in-class ALS treatment
November 09, 2022 at 11:20 AM EST
Eikonoklastes Therapeutics, a Cincinnati biotech startup developing a first-in-class treatment for ALS, otherwise known as Lou Gehrig’s Disease, received FDA approval.
